Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life: A randomized clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life : A randomized clinical trial. / Thøstesen, Lisbeth Marianne; Stensballe, Lone Graff; Pihl, Gitte Thybo; Kjærgaard, Jesper; Birk, Nina Marie; Nissen, Thomas Nørrelykke; Jensen, Aksel Karl Georg; Aaby, Peter; Olesen, Annette Wind; Jeppesen, Dorthe Lisbeth; Benn, Christine Stabell; Kofoed, Poul-Erik.

In: Journal of Allergy and Clinical Immunology, Vol. 140, No. 6, 12.2017, p. 1616-1621.e3.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Thøstesen, LM, Stensballe, LG, Pihl, GT, Kjærgaard, J, Birk, NM, Nissen, TN, Jensen, AKG, Aaby, P, Olesen, AW, Jeppesen, DL, Benn, CS & Kofoed, P-E 2017, 'Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life: A randomized clinical trial', Journal of Allergy and Clinical Immunology, vol. 140, no. 6, pp. 1616-1621.e3. https://doi.org/10.1016/j.jaci.2016.12.990

APA

Thøstesen, L. M., Stensballe, L. G., Pihl, G. T., Kjærgaard, J., Birk, N. M., Nissen, T. N., ... Kofoed, P-E. (2017). Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life: A randomized clinical trial. Journal of Allergy and Clinical Immunology, 140(6), 1616-1621.e3. https://doi.org/10.1016/j.jaci.2016.12.990

Vancouver

Thøstesen LM, Stensballe LG, Pihl GT, Kjærgaard J, Birk NM, Nissen TN et al. Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life: A randomized clinical trial. Journal of Allergy and Clinical Immunology. 2017 Dec;140(6):1616-1621.e3. https://doi.org/10.1016/j.jaci.2016.12.990

Author

Thøstesen, Lisbeth Marianne ; Stensballe, Lone Graff ; Pihl, Gitte Thybo ; Kjærgaard, Jesper ; Birk, Nina Marie ; Nissen, Thomas Nørrelykke ; Jensen, Aksel Karl Georg ; Aaby, Peter ; Olesen, Annette Wind ; Jeppesen, Dorthe Lisbeth ; Benn, Christine Stabell ; Kofoed, Poul-Erik. / Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life : A randomized clinical trial. In: Journal of Allergy and Clinical Immunology. 2017 ; Vol. 140, No. 6. pp. 1616-1621.e3.

Bibtex

@article{2ecdf6ab390046e1a651364bb94d8369,
title = "Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life: A randomized clinical trial",
abstract = "Background: Recurrent wheeze (RW) is frequent in childhood. Studies have suggested that BCG vaccination can have nonspecific effects, reducing general nontuberculosis morbidity, including respiratory tract infections and atopic diseases. The mechanisms behind these nonspecific effects of BCG are not fully understood, but a shift from a TH2 to a TH1 response has been suggested as a possible explanation. Objective: We hypothesized that BCG at birth would reduce the cumulative incidence of RW during the first year of life. Methods: The Danish Calmette Study is a multicenter randomized trial conducted from 2012-2015 at 3 Danish hospitals. The 4262 newborns of 4184 included mothers were randomized 1:1 to BCG (SSI strain 1331) or to a no-intervention control group within 7 days of birth; siblings were randomized together as one randomization unit. Exclusion criteria were gestational age of less than 32 weeks, birth weight of less than 1000 g, known immunodeficiency, or no Danish-speaking parent. Information was collected through telephone interviews and clinical examinations at 3 and 13 months of age; data collectors were blind to randomization group. RW was defined in several ways, with the main definition being physician-diagnosed and medically treated RW up to 13 months of age. Results: By 13 months, 211 (10.0{\%}) of 2100 children in the BCG group and 195 (9.4{\%}) of 2071 children in the control group had received a diagnosis of RW from a medical doctor and received antiasthma treatment (relative risk, 1.07; 95{\%} CI, 0.89-1.28). Supplementary analyses were made, including an analysis of baseline risk factors for development of RW. Conclusion: Neonatal BCG had no effect on the development of RW before 13 months of age.",
keywords = "BCG, Heterologous immunity, Infant, Nonspecific effects, Recurrent wheeze, Vaccination",
author = "Th{\o}stesen, {Lisbeth Marianne} and Stensballe, {Lone Graff} and Pihl, {Gitte Thybo} and Jesper Kj{\ae}rgaard and Birk, {Nina Marie} and Nissen, {Thomas N{\o}rrelykke} and Jensen, {Aksel Karl Georg} and Peter Aaby and Olesen, {Annette Wind} and Jeppesen, {Dorthe Lisbeth} and Benn, {Christine Stabell} and Poul-Erik Kofoed",
year = "2017",
month = "12",
doi = "10.1016/j.jaci.2016.12.990",
language = "English",
volume = "140",
pages = "1616--1621.e3",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life

T2 - A randomized clinical trial

AU - Thøstesen, Lisbeth Marianne

AU - Stensballe, Lone Graff

AU - Pihl, Gitte Thybo

AU - Kjærgaard, Jesper

AU - Birk, Nina Marie

AU - Nissen, Thomas Nørrelykke

AU - Jensen, Aksel Karl Georg

AU - Aaby, Peter

AU - Olesen, Annette Wind

AU - Jeppesen, Dorthe Lisbeth

AU - Benn, Christine Stabell

AU - Kofoed, Poul-Erik

PY - 2017/12

Y1 - 2017/12

N2 - Background: Recurrent wheeze (RW) is frequent in childhood. Studies have suggested that BCG vaccination can have nonspecific effects, reducing general nontuberculosis morbidity, including respiratory tract infections and atopic diseases. The mechanisms behind these nonspecific effects of BCG are not fully understood, but a shift from a TH2 to a TH1 response has been suggested as a possible explanation. Objective: We hypothesized that BCG at birth would reduce the cumulative incidence of RW during the first year of life. Methods: The Danish Calmette Study is a multicenter randomized trial conducted from 2012-2015 at 3 Danish hospitals. The 4262 newborns of 4184 included mothers were randomized 1:1 to BCG (SSI strain 1331) or to a no-intervention control group within 7 days of birth; siblings were randomized together as one randomization unit. Exclusion criteria were gestational age of less than 32 weeks, birth weight of less than 1000 g, known immunodeficiency, or no Danish-speaking parent. Information was collected through telephone interviews and clinical examinations at 3 and 13 months of age; data collectors were blind to randomization group. RW was defined in several ways, with the main definition being physician-diagnosed and medically treated RW up to 13 months of age. Results: By 13 months, 211 (10.0%) of 2100 children in the BCG group and 195 (9.4%) of 2071 children in the control group had received a diagnosis of RW from a medical doctor and received antiasthma treatment (relative risk, 1.07; 95% CI, 0.89-1.28). Supplementary analyses were made, including an analysis of baseline risk factors for development of RW. Conclusion: Neonatal BCG had no effect on the development of RW before 13 months of age.

AB - Background: Recurrent wheeze (RW) is frequent in childhood. Studies have suggested that BCG vaccination can have nonspecific effects, reducing general nontuberculosis morbidity, including respiratory tract infections and atopic diseases. The mechanisms behind these nonspecific effects of BCG are not fully understood, but a shift from a TH2 to a TH1 response has been suggested as a possible explanation. Objective: We hypothesized that BCG at birth would reduce the cumulative incidence of RW during the first year of life. Methods: The Danish Calmette Study is a multicenter randomized trial conducted from 2012-2015 at 3 Danish hospitals. The 4262 newborns of 4184 included mothers were randomized 1:1 to BCG (SSI strain 1331) or to a no-intervention control group within 7 days of birth; siblings were randomized together as one randomization unit. Exclusion criteria were gestational age of less than 32 weeks, birth weight of less than 1000 g, known immunodeficiency, or no Danish-speaking parent. Information was collected through telephone interviews and clinical examinations at 3 and 13 months of age; data collectors were blind to randomization group. RW was defined in several ways, with the main definition being physician-diagnosed and medically treated RW up to 13 months of age. Results: By 13 months, 211 (10.0%) of 2100 children in the BCG group and 195 (9.4%) of 2071 children in the control group had received a diagnosis of RW from a medical doctor and received antiasthma treatment (relative risk, 1.07; 95% CI, 0.89-1.28). Supplementary analyses were made, including an analysis of baseline risk factors for development of RW. Conclusion: Neonatal BCG had no effect on the development of RW before 13 months of age.

KW - BCG

KW - Heterologous immunity

KW - Infant

KW - Nonspecific effects

KW - Recurrent wheeze

KW - Vaccination

U2 - 10.1016/j.jaci.2016.12.990

DO - 10.1016/j.jaci.2016.12.990

M3 - Journal article

VL - 140

SP - 1616-1621.e3

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 6

ER -

ID: 179174189